89bio (ETNB) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-384.7M
Net Income
-367.1M
Balance Sheet Metrics
Total Assets
478.7M
Total Liabilities
77.9M
Shareholders Equity
400.8M
Debt to Equity
0.19
Cash Flow Metrics
Operating Cash Flow
-337.6M
Free Cash Flow
-367.8M
Revenue & Profitability Trend
89bio Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 384.7M | 151.2M | 102.2M | 89.7M | 49.4M |
| Operating Income | -384.7M | -151.2M | -102.2M | -89.7M | -49.4M |
| Pre-tax Income | -366.4M | -138.3M | -102.0M | -90.3M | -49.6M |
| Income Tax | 692.0K | 3.9M | 19.0K | -147.0K | -59.0K |
| Net Income | -367.1M | -142.2M | -102.0M | -90.1M | -49.5M |
| EPS (Diluted) | - | -$2.00 | -$2.93 | -$4.48 | -$3.08 |
Income Statement Trend
89bio Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 476.4M | 593.5M | 196.1M | 162.0M | 210.2M |
| Non-Current Assets | 2.2M | 2.7M | 744.0K | 440.0K | 872.0K |
| Total Assets | 478.7M | 596.3M | 196.8M | 162.4M | 211.1M |
| Liabilities | |||||
| Current Liabilities | 36.1M | 29.6M | 24.6M | 19.5M | 8.1M |
| Non-Current Liabilities | 41.8M | 30.4M | 20.4M | 16.9M | 0 |
| Total Liabilities | 77.9M | 60.0M | 45.0M | 36.5M | 8.1M |
| Equity | |||||
| Total Shareholders Equity | 400.8M | 536.3M | 151.8M | 126.0M | 203.0M |
Balance Sheet Composition
89bio Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -367.1M | -142.2M | -102.0M | -90.1M | -49.5M |
| Operating Cash Flow | -337.6M | -125.1M | -85.2M | -76.1M | -44.3M |
| Investing Activities | |||||
| Capital Expenditures | -15.0K | -4.0K | -7.0K | -63.0K | -126.0K |
| Investing Cash Flow | -40.9M | -123.0M | -33.9M | 7.2M | -106.8M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 164.0M | 497.3M | 116.7M | 23.7M | 157.5M |
| Free Cash Flow | -367.8M | -129.2M | -81.1M | -76.8M | -46.4M |
Cash Flow Trend
89bio Key Financial Ratios
Valuation Ratios
Forward P/E
-3.48
Price to Book
2.41
PEG Ratio
-3.48
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-69.30%
Return on Assets
-39.93%
Financial Health
Current Ratio
18.03
Debt to Equity
6.21
Beta
1.53
Per Share Data
EPS (TTM)
-$3.46
Book Value per Share
$4.15
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| etnb | 1.5B | - | 2.41 | -69.30% | 0.00% | 6.21 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.